Menjugate

N. meningitidis Group C (Strain C11) Oligosaccharide Conjugated To Corynebacterium Diphtheriae Crm19, the active ingredient in Menjugate, is a vaccine presented as a vaccine for intramuscular use. It prevents invasive disease caused by Neisseria meningitidis serogroup C in infants, children, adolescents and adults.

GNH USA supplies Menjugate as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Menjugate is a meningococcal group C conjugate vaccine used to prevent infections caused by Neisseria meningitidis serogroup C. - Invasive meningococcal disease (serogroup C): induces protective immunity to prevent meningitis, septicemia and related severe infections - Community outbreaks of serogroup C: reduces transmission and incidence in at‑risk populations - Travel to endemic regions with serogroup C risk: provides prophylactic protection against invasive disease

The following adverse reactions have been reported after administration of Menjugate.

Common Side Effects: - Injection site pain - Redness or swelling at injection site - Fever - Headache - Fatigue - Muscle aches

Serious or Rare Side Effects: - Anaphylaxis or severe allergic reaction - Guillain‑Barré syndrome (very rare) - High‑grade fever (>40 °C) - Seizures - Hypotension

Before administering Menjugate, consider the following precautions. - Allergy assessment: avoid use in individuals with a severe hypersensitivity to any vaccine component - Pregnancy: administer only if the potential benefit justifies the potential risk, as data are limited - Immunocompromised patients: vaccine may elicit a reduced immune response - Age‑specific schedule: follow approved dosing intervals for infants, children, adolescents and adults - Concurrent vaccinations: can be given with other vaccines at separate sites, but observe recommended intervals for live vaccines - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake

Vaccine interactions are generally limited, but the following should be considered.

Major Interactions (Avoid): - Live attenuated vaccines: avoid simultaneous administration; separate by at least 4 weeks - Blood products containing immunoglobulins: may interfere with immune response if given concurrently

Moderate Interactions (Monitor Closely): - Immunosuppressive therapy: may diminish vaccine efficacy - Antipyretics: may mask fever, but generally acceptable - Other injectable vaccines: monitor for additive local reactions